Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 455 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Solution Vehicle Clear all
Completed Phase 1 Interventional

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

NCT01597401
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Aes-103, Placebo
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults

NCT04657172
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine Ophthalmic, Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
40 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
Azusa, California • Newport Beach, California • Fort Collins, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

NCT02634853
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 2Phase 3 Interventional

Double-Blind, Multicenter, Study Comparing the Efficacy and Safety of OMS103HP With Vehicle Irrigation Solution in Subjects Undergoing Meniscectomy

NCT00624845
View directory record Official record
Conditions
Postoperative Pain
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

NCT03131154
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

NCT01904721
View directory record Official record
Conditions
Alopecia, Alopecia, Androgenetic, Baldness
Interventions
Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fridley, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 22, 2016 · Synced Oct 23, 2026, 7:37 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

NCT04293185
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
bb1111
Genetic
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
2 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 4 Interventional Results available

Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

NCT05505292
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast 5% Ophthalmic Solution, Lifitegrast Ophthalmic Solution Vehicle
Drug · Other
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin

NCT02597777
View directory record Official record
Conditions
Oily Skin
Interventions
Acetyl Hexapeptide-8, Placebo vehicle
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 2Phase 3 Interventional

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

NCT02597803
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
RGN-259, Placebo
Drug
Lead sponsor
ReGenTree, LLC
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

NCT01737762
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
HP802-247, Vehicle
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
37
States / cities
Phoenix, Arizona • Carlsbad, California • Castro Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones

NCT00857090
View directory record Official record
Conditions
Urinary Calculi, Urinary Stones, Urinary Tract Stones, Renal Calculi, Kidney Stones
Interventions
OMS201, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Orange, California • Denver, Colorado • Nasville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT00651859
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Bimatoprost 0.01% Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution, Bimatoprost Vehicle Ophthalmic Solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
20 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 2 Interventional

Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery

NCT02081703
View directory record Official record
Conditions
Postsurgical Pain
Interventions
AYX1 Injection 660 mg / 6 mL, AYX1 Injection 1100 mg / 10 mL, Placebo Injection 6 mL, Placebo Injection 10 mL
Drug
Lead sponsor
Adynxx, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Sheffield, Alabama • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 4, 2015 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 2 Interventional Results available

A Study Assessing the Safety, Efficacy, and Optimum Dosage of K-161 in Subjects With Moderate to Severe Dry Eye Disease

NCT04084483
View directory record Official record
Conditions
Dry Eye Disease
Interventions
K-161, Placebo (Vehicle)
Drug · Other
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)

NCT05914805
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Clascoterone 5% solution, Vehicle solution
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
18 Years and older · Male only
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Scottsdale, Arizona • Hollywood, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

NCT04638660
View directory record Official record
Conditions
Dim Light Vision Disturbances
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo)
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Newport Beach, California • Petaluma, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

NCT05910450
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
Clascoterone 5% solution, Vehicle solution
Drug
Lead sponsor
Cassiopea SpA
Industry
Eligibility
18 Years and older · Male only
Enrollment
703 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
North Little Rock, Arkansas • San Diego, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

In-vivo Efficacy of Patient Preoperative Prep, ZuraPrep (ZP)

NCT03782103
View directory record Official record
Conditions
Surgical Skin Preparation
Interventions
ZuraPrep Clear Solution, ChloraPrep, ZuraPrep Vehicle
Drug
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Sterling, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 23, 2026, 7:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

NCT04499248
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
AGN-193408 SR, Lumigan, Sham Administration, Lumigan Vehicle
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
42
States / cities
Sun City, Arizona • Glendale, California • Inglewood, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 23, 2026, 7:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pain and Acetaminophen in Women Study

NCT04573426
View directory record Official record
Conditions
Overweight, Obesity, Healthy Adults
Interventions
Acetaminophen, Placebo, Weight stigma vignette, Control vignette
Drug · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 23, 2026, 7:37 PM EDT
Recruiting Phase 2 Interventional

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

NCT05934448
View directory record Official record
Conditions
Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma Refractory, Primary Mediastinal Large B-Cell Lymphoma Recurrent, Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion, Leukapheresis
Drug · Procedure
Lead sponsor
Jennifer Crombie, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 23, 2026, 7:37 PM EDT
Active, not recruiting Phase 3 Interventional

Study of OT-101 in Treating Myopia

NCT04770610
View directory record Official record
Conditions
Myopia, Progressive
Interventions
OT-101 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Ocumension (Hong Kong) Limited
Other
Eligibility
3 Years to 15 Years
Enrollment
678 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Colorado Springs, Colorado • Fort Collins, Colorado • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 23, 2026, 7:37 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of Epinephrine in Endotoxemia in Normal Volunteers

NCT00753402
View directory record Official record
Conditions
Immune System
Interventions
Endotoxin, Lipopolysaccharide, LPS, Endotoxin, Epinephrine
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 27, 2015 · Synced Oct 23, 2026, 7:37 PM EDT